J&J, Amgen and Roche face growing biosimilar competition that is driving down prices: report

Five years since the U.S. saw its first mimic of a biologic drug with Sandoz’s Zarxio, new evidence suggests some innovator biologics are starting to feel the heat from their complex copycats.

Between 2019 and 2020, the percentage of specialty claims for treatments with an available biosim plummeted at a greater pace compared with previous years, according to the latest “State of Specialty Spend and Trend Report” from the Pharmaceutical Strategies Group (PSG) released on Thursday.